Back

SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms

Ebinger, J.; Botwin, G. J.; Albert, C. M.; Alotaibi, M.; Arditi, M.; Berg, A. H.; Binek, A.; Botting, P.; Fert-Bober, J.; Figueiredo, J. C.; Grein, J. D.; Hasan, W.; Henglin, M.; Hussain, S. K.; Jain, M.; Joung, S.; Karin, M.; Kim, E. H.; Li, D.; Liu, Y.; Luong, E.; McGovern, D. P. B.; Merchant, A.; Merin, N.; Miles, P. B.; Nguyen, T.-T.; Raedschelders, K.; Rashid, M. A.; Riera, C. E.; Riggs, R. V.; Sharma, S.; Sobhani, K.; Sternbach, S.; Sun, N.; Tourtellotte, W. G.; Van Eyk, J. E.; Braun, J. G.; Cheng, S.

2020-08-04 infectious diseases
10.1101/2020.08.02.20166876 medRxiv
Show abstract

Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.